Pegylated liposomal doxorubicin in the management of ovarian cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pegylated liposomal doxorubicin in the management of ovarian cancer
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 15, Issue 6, Pages 707-720
Publisher
Informa UK Limited
Online
2014-03-22
DOI
10.4161/cbt.28557
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology
- (2013) Mehmet Kucukoner et al. Asian Pacific Journal of Cancer Prevention
- The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
- (2013) J.-M. Gibson et al. ONCOLOGIST
- A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
- (2013) Nicoletta Staropoli et al. Journal of Ovarian Research
- Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial
- (2012) M. Brundage et al. ANNALS OF ONCOLOGY
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
- (2012) Bradley J. Monk et al. EUROPEAN JOURNAL OF CANCER
- Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials
- (2012) Domenico Ciliberto et al. EUROPEAN JOURNAL OF CANCER
- The changing landscape of therapeutic strategies for recurrent ovarian cancer
- (2012) Klaus H Baumann et al. Future Oncology
- Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
- (2012) Nicoletta Colombo et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents
- (2012) Aristotle Bamias et al. ONCOLOGY
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
- (2011) L. Gladieff et al. ANNALS OF ONCOLOGY
- Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
- (2011) A. Lortholary et al. ANNALS OF ONCOLOGY
- First-Line Therapy in Ovarian Cancer Trials
- (2011) Tate Thigpen et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Clinical Trials in Recurrent Ovarian Cancer
- (2011) Michael Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial
- (2011) Sandro Pignata et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
- (2010) A. Poveda et al. ANNALS OF ONCOLOGY
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) N. Colombo et al. ANNALS OF ONCOLOGY
- Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience
- (2010) Rachel F DEAR et al. Asia-Pacific Journal of Clinical Oncology
- Systematic review and meta-analysis methodology
- (2010) M. Crowther et al. BLOOD
- A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
- (2010) Dimitrios Bafaloukos et al. BMC Medicine
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer
- (2010) Gregor Seliger et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
- (2010) Ignace Vergote et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
- (2010) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough?
- (2010) Stephen A. Cannistra JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research
- (2010) Susan Armijo-Olivo et al. JOURNAL OF EVALUATION IN CLINICAL PRACTICE
- Review: Practical considerations in ovarian cancer chemotherapy
- (2010) Mihaela Cristea et al. Therapeutic Advances in Medical Oncology
- Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer
- (2009) Sandro Pignata et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
- (2009) I. Vergote et al. EUROPEAN JOURNAL OF CANCER
- Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
- (2009) Maurie Markman et al. GYNECOLOGIC ONCOLOGY
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
- (2009) Michael A. Bookman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
- (2008) Gabriella Ferrandina et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)
- (2007) David S. Alberts et al. GYNECOLOGIC ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More